3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
10
Breast Neoplasms
10
Urinary Bladder Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
Pemetrexed
5
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cisplatin
4
fludarabine
3
Cyclophosphamide
3
Radiotherapy, Intensity-Modulated
2
Cerebral Decortication
2
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
avelumab
1
atezolizumab
1
Platinum
1
Influenza Vaccines
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Blood Component Removal
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
durvalumab
×
90 days
×
Clear all
No trials found.